vs
ARTIVION, INC.（AORT）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是ARTIVION, INC.的1.7倍（$200.5M vs $116.0M），ROGERS CORP净利率更高（2.2% vs 2.1%，领先0.2%），ARTIVION, INC.同比增速更快（19.2% vs 5.2%），ROGERS CORP自由现金流更多（$1.1M vs $-7.9M），过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs -3.3%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
AORT vs ROG — 直观对比
营收规模更大
ROG
是对方的1.7倍
$116.0M
营收增速更快
AORT
高出14.0%
5.2%
净利率更高
ROG
高出0.2%
2.1%
自由现金流更多
ROG
多$9.0M
$-7.9M
两年增速更快
AORT
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $200.5M |
| 净利润 | $2.4M | $4.5M |
| 毛利率 | 63.1% | 32.2% |
| 营业利润率 | 9.2% | — |
| 净利率 | 2.1% | 2.2% |
| 营收同比 | 19.2% | 5.2% |
| 净利润同比 | 114.7% | 421.4% |
| 每股收益（稀释后） | $0.06 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $116.0M | $201.5M | ||
| Q3 25 | $113.4M | $216.0M | ||
| Q2 25 | $113.0M | $202.8M | ||
| Q1 25 | $99.0M | $190.5M | ||
| Q4 24 | $97.3M | $192.2M | ||
| Q3 24 | $95.8M | $210.3M | ||
| Q2 24 | $98.0M | $214.2M |
净利润AORTROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $2.4M | $4.6M | ||
| Q3 25 | $6.5M | $8.6M | ||
| Q2 25 | $1.3M | $-73.6M | ||
| Q1 25 | $-505.0K | $-1.4M | ||
| Q4 24 | $-16.5M | $-500.0K | ||
| Q3 24 | $-2.3M | $10.7M | ||
| Q2 24 | $-2.1M | $8.1M |
毛利率AORTROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 63.1% | 31.5% | ||
| Q3 25 | 65.6% | 33.5% | ||
| Q2 25 | 64.7% | 31.6% | ||
| Q1 25 | 64.2% | 29.9% | ||
| Q4 24 | 63.2% | 32.1% | ||
| Q3 24 | 63.7% | 35.2% | ||
| Q2 24 | 64.6% | 34.1% |
营业利润率AORTROG
| Q1 26 | — | — | ||
| Q4 25 | 9.2% | 3.5% | ||
| Q3 25 | 11.1% | 7.3% | ||
| Q2 25 | 7.4% | -33.3% | ||
| Q1 25 | 2.2% | -0.2% | ||
| Q4 24 | 2.7% | -6.6% | ||
| Q3 24 | 4.6% | 6.9% | ||
| Q2 24 | 6.6% | 5.3% |
净利率AORTROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 2.1% | 2.3% | ||
| Q3 25 | 5.7% | 4.0% | ||
| Q2 25 | 1.2% | -36.3% | ||
| Q1 25 | -0.5% | -0.7% | ||
| Q4 24 | -16.9% | -0.3% | ||
| Q3 24 | -2.4% | 5.1% | ||
| Q2 24 | -2.2% | 3.8% |
每股收益（稀释后）AORTROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.06 | $0.20 | ||
| Q3 25 | $0.13 | $0.48 | ||
| Q2 25 | $0.03 | $-4.00 | ||
| Q1 25 | $-0.01 | $-0.08 | ||
| Q4 24 | $-0.40 | $-0.04 | ||
| Q3 24 | $-0.05 | $0.58 | ||
| Q2 24 | $-0.05 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $195.8M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $1.2B |
| 总资产 | $884.8M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $64.9M | $197.0M | ||
| Q3 25 | $73.4M | $167.8M | ||
| Q2 25 | $53.5M | $157.2M | ||
| Q1 25 | $37.7M | $175.6M | ||
| Q4 24 | $53.5M | $159.8M | ||
| Q3 24 | $56.2M | $146.4M | ||
| Q2 24 | $55.0M | $119.9M |
总债务AORTROG
| Q1 26 | — | — | ||
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — |
股东权益AORTROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $448.2M | $1.2B | ||
| Q3 25 | $438.7M | $1.2B | ||
| Q2 25 | $419.9M | $1.2B | ||
| Q1 25 | $294.3M | $1.3B | ||
| Q4 24 | $276.2M | $1.3B | ||
| Q3 24 | $304.7M | $1.3B | ||
| Q2 24 | $295.1M | $1.3B |
总资产AORTROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $884.8M | $1.4B | ||
| Q3 25 | $857.7M | $1.4B | ||
| Q2 25 | $838.4M | $1.5B | ||
| Q1 25 | $791.2M | $1.5B | ||
| Q4 24 | $789.1M | $1.5B | ||
| Q3 24 | $803.1M | $1.5B | ||
| Q2 24 | $789.5M | $1.5B |
负债/权益比AORTROG
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $1.1M |
| 自由现金流率自由现金流/营收 | -6.9% | 0.5% |
| 资本支出强度资本支出/营收 | 23.7% | 2.3% |
| 现金转化率经营现金流/净利润 | 8.06× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $839.0K | $70.1M |
8季度趋势，按日历期对齐
经营现金流AORTROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $19.6M | $46.9M | ||
| Q3 25 | $22.3M | $28.9M | ||
| Q2 25 | $15.0M | $13.7M | ||
| Q1 25 | $-17.0M | $11.7M | ||
| Q4 24 | $10.1M | $33.7M | ||
| Q3 24 | $11.5M | $42.4M | ||
| Q2 24 | $6.1M | $22.9M |
自由现金流AORTROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-7.9M | $42.2M | ||
| Q3 25 | $17.7M | $21.2M | ||
| Q2 25 | $11.7M | $5.6M | ||
| Q1 25 | $-20.6M | $2.1M | ||
| Q4 24 | $8.7M | $18.3M | ||
| Q3 24 | $7.8M | $25.2M | ||
| Q2 24 | $3.6M | $8.8M |
自由现金流率AORTROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | -6.9% | 20.9% | ||
| Q3 25 | 15.6% | 9.8% | ||
| Q2 25 | 10.4% | 2.8% | ||
| Q1 25 | -20.8% | 1.1% | ||
| Q4 24 | 9.0% | 9.5% | ||
| Q3 24 | 8.2% | 12.0% | ||
| Q2 24 | 3.7% | 4.1% |
资本支出强度AORTROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 23.7% | 2.3% | ||
| Q3 25 | 4.1% | 3.6% | ||
| Q2 25 | 2.9% | 4.0% | ||
| Q1 25 | 3.7% | 5.0% | ||
| Q4 24 | 1.5% | 8.0% | ||
| Q3 24 | 3.8% | 8.2% | ||
| Q2 24 | 2.6% | 6.6% |
现金转化率AORTROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 8.06× | 10.20× | ||
| Q3 25 | 3.42× | 3.36× | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
ROG
暂无分部数据
